Legend Biotech Corporation (LEGN) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
5.14
↓-31% vs avg
5yr avg: 7.48
30Y Low4.0·High10.7
ROE
↑
-29.1%
↓+32% vs avg
5yr avg: -42.9%
30Y Low-112%·High77%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.0·High29.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LEGN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Legend Biotech Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.2B | $4.0B | $5.9B | $10.6B | $7.9B | $6.6B | $3.3B | — | — | — |
| Enterprise Value | $4.7B | $3.5B | $6.0B | $9.6B | $7.4B | $6.0B | $2.9B | — | — | — |
| P/E Ratio → | -17.46 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 5.02 | 3.89 | 9.49 | 37.16 | 67.86 | 95.39 | 44.36 | — | — | — |
| P/B Ratio | 5.14 | 4.00 | 5.72 | 8.47 | 10.67 | 8.57 | 5.57 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LEGN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.42 | 9.59 | 33.83 | 63.57 | 87.16 | 38.33 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
LEGN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Legend Biotech Corporation earns an operating margin of -13.3%. Operating margins have expanded from -154.1% to -13.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -29.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.3% | 60.3% | 62.6% | 49.4% | 44.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.4% |
| Operating Margin | -13.3% | -13.3% | -48.3% | -154.1% | -389.4% | -570.0% | — | -214.4% | -3.1% | 58.4% |
| Net Profit Margin | -28.8% | -28.8% | -28.2% | -181.8% | -381.5% | -586.4% | -355.2% | -164.4% | -5.7% | 39.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -29.1% | -29.1% | -15.4% | -51.9% | -59.1% | -59.2% | -112.2% | — | -26.7% | 77.0% |
| ROA | -17.4% | -17.4% | -10.1% | -32.6% | -36.4% | -43.8% | -52.8% | -28.3% | -0.8% | 3.9% |
| ROIC | -12.7% | -12.7% | -32.3% | -120.9% | -154.3% | -170.4% | — | — | — | 100.2% |
| ROCE | -11.0% | -11.0% | -20.1% | -33.0% | -47.4% | -52.4% | — | -61.7% | -0.7% | 7.4% |
LEGN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $902M exceeds total debt of $414M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.41 | 0.41 | 0.34 | 0.26 | 0.38 | 0.16 | 0.01 | — | 0.50 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 28.97 | 0.02 |
| Net Debt / Equity | — | -0.49 | 0.06 | -0.76 | -0.67 | -0.74 | -0.76 | — | -23.80 | -0.15 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | -1381.54 | -0.13 |
| Debt / FCF | — | — | — | — | — | — | — | — | -0.72 | — |
| Interest Coverage | -12.21 | -12.21 | -6.32 | -22.87 | -40.29 | -451.44 | -73.20 | -594.23 | -18.71 | — |
Net cash position: cash ($902M) exceeds total debt ($414M)
LEGN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.96x means Legend Biotech Corporation can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 6.92x to 1.96x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.96 | 1.96 | 4.62 | 6.92 | 3.69 | 4.14 | 5.14 | 1.62 | 2.05 | 4.43 |
| Quick Ratio | 1.91 | 1.91 | 4.54 | 6.83 | 3.66 | 4.14 | 5.12 | 1.61 | 2.05 | 4.43 |
| Cash Ratio | 1.49 | 1.49 | 4.04 | 6.05 | 3.44 | 3.85 | 4.38 | 1.25 | 1.36 | 0.04 |
| Asset Turnover | — | 0.59 | 0.38 | 0.15 | 0.09 | 0.06 | 0.10 | 0.21 | 0.11 | 0.10 |
| Inventory Turnover | 12.75 | 12.75 | 9.81 | 7.42 | 6.31 | — | — | — | — | -8.73 |
| Days Sales Outstanding | — | 88.79 | 72.67 | 201.05 | 138.87 | 310.49 | 402.06 | 211.19 | 806.53 | 3538.66 |
LEGN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Legend Biotech Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $184M | $183M | $176M | $159M | $141M | $118M | $132M | $100M | $132M |
Peer Comparison
Compare LEGN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LEGNYou | $5B | -17.5 | — | — | 60.3% | -13.3% | -29.1% | -12.7% | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 EDIT | $263M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 BMY | $110B | 15.7 | 8.9 | 8.6 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 ALNY | $37B | 119.4 | 65.9 | 79.7 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 SRPT | $2B | -2.5 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 IONS | $12B | -31.1 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 RCUS | $2B | -7.4 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
LEGN — Frequently Asked Questions
Quick answers to the most common questions about buying LEGN stock.
What is Legend Biotech Corporation's P/E ratio?
Legend Biotech Corporation's current P/E ratio is -17.5x. This places it at the 50th percentile of its historical range.
What is Legend Biotech Corporation's ROE?
Legend Biotech Corporation's return on equity (ROE) is -29.1%. The historical average is -34.6%.
Is LEGN stock overvalued?
Based on historical data, Legend Biotech Corporation is trading at a P/E of -17.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Legend Biotech Corporation's profit margins?
Legend Biotech Corporation has 60.3% gross margin and -13.3% operating margin.